FLAGYL I.V.

LOE Approaching

metronidazole hydrochloride

Pfizer

NDAINJECTIONINJECTABLEPriority Review

Approved

Nov 1980

Lifecycle

LOE Approaching

Competitive Pressure

30/100

Data completeness

3/8 — Basic

Priority Review

FLAGYL I.V. (metronidazole hydrochloride) by Pfizer is (metronidazole and tetracycline hydrochloride) and bismuth subcitrate potassium [see microbiology ()] . Approved for duodenal ulcer disease (active, history of within the past 5 years) to eradicate h. First approved in 1980.

Drug data last refreshed Yesterday

Mechanism of Action

(metronidazole and tetracycline hydrochloride) and bismuth subcitrate potassium [see Microbiology ()] .

Indications (2)

duodenal ulcer disease (active history of within the past 5 years) to eradicate H

Worked on FLAGYL I.V. at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.